Skip to main content
. Author manuscript; available in PMC: 2021 Jun 17.
Published in final edited form as: Lancet Oncol. 2020 May;21(5):710–722. doi: 10.1016/S1470-2045(20)30061-9

Figure 2: Kaplan–Meier estimates of CFI, TFST, PFS2, and TSST in the ITT population.

Figure 2:

The ITT population consisted of 375 patients in the rucaparib group and 189 patients in the placebo group. CFI=chemotherapy-free interval. HR=hazard ratio. ITT=intention to treat. PFS2=time to disease progression on subsequent therapy or death. TFST=time to start of first subsequent therapy. TSST=time to start of second subsequent therapy.